Germany Drug Pricing Policies Draw US Section 301 Scrutiny

Germany drug pricing policies have become the subject of a US trade case. In written evidence and live testimony to the Office of the US Trade Representative, AbbVie executive vice president, chief counsel and secretary Perry Siatis argued that the country’s approach to setting medicine prices and deciding which treatments are reimbursed has moved beyond a budget question and now unsettles the incentives that produce new treatments.

His submission forms part of a Section 301 investigation, the US process for examining whether another country’s acts, policies and practices are unreasonable or discriminatory and burden American commerce. Siatis wrote that AbbVie, an American drug manufacturer, has seen the effects of German policy at first hand, and that the company therefore had both a reason and a responsibility to put its perspective on the record.

What the Section 301 investigation covers

Three mechanisms stand at the center of the complaint: government price setting, mandatory rebates and reimbursement restrictions. In Siatis’s account they treat medical innovation as a burden to be managed rather than an investment in future health. Germany, he notes, is one of the world’s largest and wealthiest economies, so its choices carry beyond its own borders and risk setting a precedent that other countries follow.

Ad

The machinery he describes is familiar to anyone who works in European market access. New medicines in Germany go through an early benefit assessment introduced under AMNOG in 2011, with the Institute for Quality and Efficiency in Health Care (IQWiG) producing the assessments that feed the rebate negotiations which follow.

The cost of innovation, and who pays it

The core claim in the filing concerns arithmetic rather than principle. Suppressing the value of medicines does not remove the cost of innovation; it moves that cost somewhere else, in this case onto the US healthcare system, and weakens the American life sciences industry that supports research, clinical excellence, high-skilled jobs and manufacturing. Wealthy countries, Siatis argues, benefit from American innovation while contributing far less to the global investment that makes it possible, an imbalance he describes as deepening.

The charge that pricing pressure outside the US lands on American payers is a recurring theme in transatlantic drug policy, and it has run through Syenza’s coverage of most-favored-nation pricing, where Washington has pushed for the prices paid abroad to be reflected in what US payers are charged.

How Germany drug pricing policies reach patients

Siatis puts the patient consequences first among the side effects, even though they fall outside the direct scope of the trade investigation. When policy systematically undervalues innovation, he argues, investment becomes harder to sustain, the pace of discovery can slow, and patients may wait longer for treatments or never see them at all.

He is careful not to dismiss the other side of the ledger. Governments face legitimate and growing fiscal pressure, and more spending on health cannot be decided in isolation from priorities elsewhere in the budget, from how resources are allocated, or from where existing spending delivers more value. His objection is to the answer that follows from those constraints: constraining access or systematically undervaluing medicines to balance finite budgets.

Doubts from inside Europe

His submission points to stakeholders across Europe who have become increasingly vocal that these approaches make their markets less attractive for research, investment and new product launches, a complaint that surfaces in national pricing and pharmaceutical policy debates across the region. Germany itself has recognized the risk, he writes, and recently established a joint working group with France to ensure the continued availability of innovative medicines.

Why the failures count too

Siatis concedes that the cost of innovation argument has been litigated at length, then makes the case from drug development’s own record book. For every compound that changed the course of a disease, he writes, there are countless others that failed. He recalls an oncology researcher at his company who held celebratory memorial services for the compounds that did not make it, on the grounds that those failures were the necessary building blocks of transformative science. “Now, we have medicines on the market that save lives, thanks to that graveyard of molecules,” he wrote.

An argument, not a verdict

It is worth being clear about what has been filed. This is a submission from one manufacturer to a trade investigation, setting out a position rather than reporting a finding, and the conclusions USTR draws from the record are still to come. The measures Siatis describes were introduced by a government balancing access, innovation and cost inside a statutory insurance system, and the fiscal constraints he acknowledges are the same ones driving the price controls he criticizes. Budget impact tests and international price comparisons are the instruments European payers use to hold spending down.

What the filing does make clear is where the industry wants the next conversation to happen. Siatis closes by arguing that countries which benefit from medical breakthroughs should contribute fairly to the system that produces them, and that the Section 301 process offers a chance to work through the disagreement with evidence rather than rhetoric, for patients waiting on the next treatment to arrive. The European side of that trade-off is set out in Syenza’s reporting on EU medicine access challenges.

Source: Perry Siatis, “Germany’s Drug Pricing Policies Put Future Breakthroughs at Risk,” RealClearHealth, 22 September 2026.